The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy

Bioorganic and Medicinal Chemistry

Volumn 9, Issue 2, 2001, Pages 537-554

  McLay, Iain M ^a   Halley, Frank ^a   Souness, John E ^a   McKenna, Jeffrey ^a   Benning, Veronique ^a   Birrell, Mark ^a   Burton, Brenda ^a   Belvisi, Maria ^a   Collis, Alan ^a   Constan, Alex ^a   Foster, Martyn ^a   Hele, David ^a   Jayyosi, Zaid ^a   Kelley, Mike ^a   Maslen, Chris ^a   Miller, Glen ^a   Ouldelhkim, Marie Claude ^a   Page, Kenneth ^a   Phipps, Simon ^a   Pollock, Kenneth ^a   Porter, Barry ^a   Ratcliffe, Andrew J ^a   Redford, Elisabeth J ^a   Webber, Stephen ^a   Slater, Bryan ^a   Thybaud, Veronique ^a   Wilsher, Nicola ^a   more..

^a Dagenham Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 DIOXANYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (5 METHYL 5 MORPHOLINOCARBONYL 1,3 DIOXAN 2 YL) 5 (4 PYRIDINYL)IMIDAZOLE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RPR 132331; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BACTERIAL CELL WALL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; ENZYME INHIBITION; INCIDENCE; MONOCYTE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP1A1; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; LIPOPOLYSACCHARIDES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035086636     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(00)00331-X     Document Type: Article

References (34)

1. Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors
2. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
3. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells
4. Review, pulmonary-allergy, dermatological, gastrointestinal and arthritis
5. Acyl-CoA:cholesterol O-acyltransferase (ACAT) inhibitors. 2.2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT
6. Pharmacological profile of SB203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxic shock and immune function
7. Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes
8. Pharmacological effects of SB 2200025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models
9. p38 MAP kinase inhibitors: Progress and possibilities
10. ATP site directed kinase inhibitors
11. Intracellular signaling and proteinase inhibition
12. Pyrrols and other heterocycles as inhibitors of p38 kinase
13. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): A potent and selective p38 kinase inhibitor
14. Inhibitors of p38 MAP kinase: Therapeutic intervention in cytokine-mediated disease
15. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
16. New inhibitors of p38 kinase
17. VX-745 Vertex Pharmaceuticals
18. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
19. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase
20. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket
21. SK&F 105809 initiates and promotes hepatic foci in rats
22. Comparative biochemical and morphometric changes associated with induction of the hepatic mixed function oxidase system in the rat
23. Evaluation of the micronucleus test in vitro using Chinese hamster cells: Results of four chemicals weakly positive in the in vivo micronucleus test
24. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis
25. ACAT inhibitors: Evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents
26. 1-Substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency
27. Chemical development and scale-up of RPR200765A, a novel p38 anti-inflammatory candidate
28. Synthesis of amino-containing phosphines. The use of iminophosphorane as a protecting group for primary amines
29. Methods for detecting carciogens and mutagens with the salmonella/mammalian-microsome mutagenicity test